LabCorp and Walgreens will create co-branded testing centers within seven Walgreens located in Denver, North Carolina, and Illinois.
The assay was cleared and CLIA-waived for use on Quidel's Sofia 2 instrument for the detection of RSV using nasopharyngeal swab and nasopharyngeal aspirate/wash specimens.
Sweden-based Immunovia is preparing to launch its first diagnostic — a liquid biopsy test for pancreatic cancer — in 2018.
The distribution deal comes less than a month after the firm announced that the FDA cleared for marketing the revogene instrument along with the GenePOC GBS LB assay.
SOL will help Personal Genomics to further develop its research projects and implement its new facility dedicated to DNA sequencing.
The firm established an "at-the-market" program to offer up to $21.2 million of its common stock from time to time. Proceeds will be used for business operations.
The firms will develop tests in the hematology oncology space where detecting large structural variations of the genome is crucial for accurate diagnoses.
The deal with Aetna includes coverage for Interpace's ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier.
The firm's real-time PCR assay for rapid detection and differentiation of novovirus genogroup I and II runs on the Aries sample-to-answer system.
The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.
The clinical laboratory giant signed a nonbinding letter of intent to buy Cape Cod Healthcare's outreach lab. Its hospital-based lab is not part of the deal, however.
The foundation will provide funding of no more than $20 million over the four-year term of the deal, and no more than $6 million each year.
Axon will distribute Biosurfit's POC instrument as part of the deal, which follows earlier agreements between the two firms covering Austria, Croatia, Slovakia, the Czech Republic, and Slovenia.
The deal with Viagene is for Streck's cell stabilization products, while the agreement with Medico also includes Streck's molecular products.
The companies will develop a smartphone-based platform to offer molecular tests enabling the precision treatment of psychiatric disorders.
The test, designed to simultaneously detect diarrhea-causing enteric viruses using DNA extracted from a stool sample, includes norovirus GI, norovirus GII, and others.
Quest said that Walmart shoppers will get the diagnostic insights they need through the provision of laboratory testing and other healthcare services.
The assay can also be used to assess a broad range of metabolic conditions, including pancreatic tumors, liver disease, acromegaly, and others.
Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests.
The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.
OncoDNA said that it will use next-generation sequencing and immunohistochemistry assays to analyze patient to identify potential biomarkers and molecular alterations.
The collaboration will leverage DiaSorin's Liaion MDX PCR system, and Tecan's Fluent Laboratory Automation Solution to provide users a complete sample-to-result system.
The kit is designed to be used on the same platform as Grifols' other molecular typing platforms and can provide results within four hours of DNA extraction.
The fourth-generation assay is for the in vitro qualitative assessment of HIV-1 p24 antigen and antibodies to HIV-1 and HIV-2 in human serum and plasma.
The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments.